- Home
- CGON vs CMPR Comparison
CGON vs CMPR Comparison
Compare CGON & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- CMPR
- Stock Information
- Founded
- CGON 2010
- CMPR 1994
- Country
- CGON United States
- CMPR Ireland
- Employees
- CGON N/A
- CMPR N/A
- Industry
- CGON
- CMPR Publishing
- Sector
- CGON
- CMPR Consumer Discretionary
- Exchange
- CGON NYSE
- CMPR Nasdaq
- Market Cap
- CGON 1.3B
- CMPR 1.1B
- IPO Year
- CGON 2024
- CMPR N/A
- Fundamental
- Price
- CGON $25.62
- CMPR $44.44
- Analyst Decision
- CGON Strong Buy
- CMPR Strong Buy
- Analyst Count
- CGON 10
- CMPR 2
- Target Price
- CGON $64.00
- CMPR $62.50
- AVG Volume (30 Days)
- CGON 1.4M
- CMPR 197.9K
- Earning Date
- CGON 05-13-2025
- CMPR 07-30-2025
- Dividend Yield
- CGON N/A
- CMPR N/A
- EPS Growth
- CGON N/A
- CMPR 83.61
- EPS
- CGON N/A
- CMPR 5.97
- Revenue
- CGON $662,000.00
- CMPR $3,366,207,000.00
- Revenue This Year
- CGON N/A
- CMPR $4.77
- Revenue Next Year
- CGON $12,387.03
- CMPR $3.04
- P/E Ratio
- CGON N/A
- CMPR $7.45
- Revenue Growth
- CGON 224.51
- CMPR 3.64
- 52 Week Low
- CGON $14.80
- CMPR $35.21
- 52 Week High
- CGON $40.47
- CMPR $104.92
- Technical
- Relative Strength Index (RSI)
- CGON 53.27
- CMPR 53.29
- Support Level
- CGON $24.79
- CMPR $41.88
- Resistance Level
- CGON $26.60
- CMPR $44.27
- Average True Range (ATR)
- CGON 1.39
- CMPR 1.21
- MACD
- CGON -0.01
- CMPR 0.04
- Stochastic Oscillator
- CGON 48.52
- CMPR 40.99
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.